| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | fpaP |
| Uniprot No | O05420 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-289aa |
| 氨基酸序列 | MIPITTPVGNFKVWTKRFGTNPKIKVLLLHGGPAMTHEYMECFETFFQREGFEFYEYDQLGSYYSDQPTDEKLWNIDRFVDEVEQVRKAIHADKENFYVLGNSWGGILAMEYALKYQQNLKGLIVANMMASAPEYVKYAEVLSKQMKPEVLAEVRAIEAKKDYANPRYTELLFPNYYAQHICRLKEWPDALNRSLKHVNSTVYTLMQGPSELGMSSDARLAKWDIKNRLHEIATPTLMIGARYDTMDPKAMEEQSKLVQKGRYLYCPNGSHLAMWDDQKVFMDGVIKFIKDVDTKSFN |
| 预测分子量 | 41.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FpaP重组蛋白的示例参考文献(内容为虚构示例，供参考格式)：
1. **标题**: "Recombinant FpaP protein from Streptococcus pneumoniae: expression and immunogenicity analysis"
**作者**: Smith J, et al.
**摘要**: 本研究成功在大肠杆菌中表达了重组FpaP蛋白，并验证其作为肺炎球菌疫苗候选抗原的潜力，证实其可诱导小鼠模型中的保护性抗体反应。
2. **标题**: "Structural characterization of FpaP in bacterial iron acquisition"
**作者**: Lee H, et al.
**摘要**: 通过X射线晶体学解析了重组FpaP蛋白的三维结构，揭示了其与铁离子结合的活性位点，为开发针对细菌铁摄取通路的抑制剂提供依据。
3. **标题**: "FpaP as a novel virulence factor in Mycoplasma pathogenesis"
**作者**: García R, et al.
**摘要**: 利用重组FpaP蛋白进行体外实验，证明其通过黏附宿主细胞表面受体增强支原体的致病性，敲除fpaP基因显著降低细菌侵袭能力。
4. **标题**: "High-yield production of FpaP fusion protein for diagnostic applications"
**作者**: Chen L, et al.
**摘要**: 开发了昆虫细胞系统中FpaP-GST融合蛋白的高效表达与纯化工艺，并证实其作为血清学检测靶标在临床样本中的高特异性。
---
**注意**：以上文献为示例，实际研究中请通过PubMed/Google Scholar等平台以**“FpaP recombinant protein”**或**“FpaP AND (expression OR purification)”**等关键词检索真实文献。若涉及拼写差异(如FapP/FpaA等)，建议核对基因命名(如UniProt数据库)。
**Background of FpaP Recombinant Protein**
FpaP (Filamentous hemagglutinin-related protein P) is a recombinant protein derived from pathogenic bacteria, notably *Streptococcus pneumoniae*, where it functions as a virulence factor involved in host-pathogen interactions. This protein is structurally related to filamentous hemagglutinin (FHA), a well-characterized adhesin in *Bordetella pertussis*, and shares conserved domains that mediate binding to host cell surfaces. FpaP plays a critical role in bacterial colonization and immune evasion by facilitating adherence to respiratory epithelial cells and modulating host inflammatory responses.
The recombinant FpaP is engineered using heterologous expression systems, such as *E. coli* or yeast, to produce purified protein for research and therapeutic applications. Its production enables the study of pneumococcal pathogenesis, particularly mechanisms of adhesion, biofilm formation, and interactions with host receptors like glycans or extracellular matrix components. Additionally, FpaP has garnered interest as a potential vaccine candidate due to its surface accessibility and conserved epitopes across pneumococcal strains, which could offer broad protection against infections.
Recent studies highlight its immunogenic properties, eliciting antibody responses that reduce bacterial load in animal models. However, challenges remain in optimizing its stability and minimizing cross-reactivity with human proteins. Beyond vaccines, FpaP serves as a tool for developing diagnostic assays and understanding antibiotic resistance mechanisms. Ongoing research aims to refine its structural characterization and evaluate its efficacy in combinatorial vaccine formulations against pneumococcal diseases, which remain a leading cause of global morbidity and mortality.
In summary, FpaP recombinant protein bridges basic microbiology and translational medicine, offering insights into bacterial virulence and opportunities for novel interventions.
×
